TNF抑制剂治疗银屑病关节炎的疗效与药物生存:前瞻性队列研究
基于芬兰ROB-FIN注册中心2004—2014年765例PsA患者共990个TNF抑制剂治疗疗程,评估疗效与药物生存。6个月EULAR中度应答率一线为68%、二/三线为37%;12和24个月停药概率分别为20%和28%。阿达木单抗药物生存优于英夫利西单抗(HR=0.62,95%CI 0.44-0.88)。
要点
- 一线TNF抑制剂6个月EULAR中度应答率68%,二/三线降至37%。
- 12和24个月停药概率分别为20%和28%。
- 阿达木单抗药物生存优于英夫利西单抗(HR=0.62,95%CI 0.44-0.88)。
核心结论
- 所有可用TNF抑制剂在联用或不联用csDMARDs时疗效相似。
- 阿达木单抗相比英夫利西单抗与更好的药物生存相关。
研究设计与样本
- 基于芬兰国家生物制剂治疗注册中心(ROB-FIN)的前瞻性队列研究。
- 纳入2004—2014年间开始第一、第二或第三疗程TNF抑制剂治疗的PsA患者,共765例、990个治疗疗程。
- 疗效采用ACR和EULAR应答标准评估并以有序logistic回归建模;治疗持续性采用Kaplan-Meier生存分析和Cox比例风险模型分析。
主要发现
- 第一疗程使用者中68%在6个月达到EULAR中度应答,第二或第三疗程使用者中为37%。
- 12个月和24个月内停药概率分别为20%和28%。
- 校正后各TNF抑制剂治疗应答相似,联用csDMARDs与更好疗效无关。
- 阿达木单抗药物生存优于英夫利西单抗(HR=0.62;95%CI:0.44-0.88)。
- 依那西普(HR=0.77,95%CI:0.55-1.1)和戈利木单抗(HR=0.75,95%CI:0.46-1.2)与英夫利西单抗无差异,联用csDMARDs未统计学改善药物生存。
关键数值与推荐
- 6个月EULAR中度应答率:第一疗程68%,第二或第三疗程37%。
- 12个月和24个月停药概率分别为20%和28%。
- 阿达木单抗vs英夫利西单抗药物生存HR=0.62(95%CI:0.44-0.88)。
- 依那西普vs英夫利西单抗HR=0.77(95%CI:0.55-1.1);戈利木单抗vs英夫利西单抗HR=0.75(95%CI:0.46-1.2)。
临床怎么用
- PsA患者选择TNF抑制剂时,各药物疗效相似,可结合药物生存数据个体化选择。
- 阿达木单抗在药物生存方面优于英夫利西单抗,可作为考虑因素之一。
- 联用csDMARDs未显示改善TNF抑制剂疗效或药物生存,决策时需权衡。
局限性
- 本文为观察性注册研究,未报告随机化或盲法设计。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Tumor necrosis factor (TNF)-inhibitors are used to treat psoriatic arthritis (PsA), but only a limited number of observational studies on this subject have been published thus far. The aim of this research was to analyze the effectiveness and drug survival of TNF-inhibitors in the treatment of PsA. METHODS: PsA patients identified from the National Register for Biologic Treatment in Finland (ROB-FIN) starting their first, second, or third TNF-inhibitor treatment between 2004 and 2014 were included. Effectiveness was measured using ACR and EULAR response criteria and modeled using ordinal logistic regression. Treatment persistence was analyzed using Kaplan-Meier survival analysis and Cox proportional hazards model. RESULTS: The study comprised 765 patients and 990 TNF-inhibitor treatment courses. EULAR moderate treatment responses at 6 months were achieved by 68% and 37% of the users of the first and the second or the third biologic, respectively. The probabilities of discontinuing the treatment within 12 and 24 months were 20% and 28%, respectively. Adjusted treatment responses to all TNF-inhibitors were similar; however, co-therapy with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) was not associated with better effectiveness. Adalimumab [hazard ratio (HR) = 0.62; 95% confidence interval (CI): 0.44-0.88] was superior to infliximab in drug survival while etanercept (HR = 0.77, 95% CI: 0.55-1.1) and golimumab (HR = 0.75, 95% CI: 0.46-1.2) did not differ from it. Co-medication with csDMARDs did not statistically improve drug survival. CONCLUSION: All available TNF-inhibitors showed similar treatment responses with or without csDMARDs. Adalimumab was associated with better drug survival when compared to infliximab.
引用
- Aaltonen K, Heinonen A, Joensuu J, et al. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study. Semin Arthritis Rheum. 2016. PMID: 28010883. doi:10.1016/j.semarthrit.2016.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。